Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Gastric Cancer

Clinical and regulatory intelligence for Gastric Cancer with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
9
Catalysts
0
Assets
7

Relevant assets

AI →
ASP2138 →
BCL6 →
Intramuscular →
nivolumab →
Novel →
Phase →

Relevant companies

Astellas Pharma →

Recent signals(9)

ClinicalAugust 2, 2026

Phase II Study on HIPEC's Impact on PD-L1 in Advanced Gastric Cancer

The study aims to evaluate the upregulation of PD-L1 expression in peritoneal metastases from gastric cancer following HIPEC treatment.

ClinicalJuly 25, 2026

Astellas Pharma initiates trial of ASP2138 for HER2-negative gastric cancer

Astellas Pharma is conducting a double-blind study to evaluate ASP2138 in combination with chemotherapy and pembrolizumab for patients with HER2-negative and CLDN18.2-positive gastric or gastroesophageal junction cancer.

ClinicalJuly 19, 2026

Intramuscular PDX Models Show High Engraftment for Gastric Cancer Drug Testing

An optimized intramuscular patient-derived xenograft (PDX) platform demonstrates high engraftment rates in gastric cancer, enhancing individualized drug testing and biomarker discovery.

ClinicalJuly 17, 2026

AI Model for Predicting Neoadjuvant Chemo Response in Advanced Gastric Cancer

A prospective cohort study is underway to develop an AI model predicting chemotherapy response using imaging and liquid biopsy.

ClinicalJuly 9, 2026

Novel compound AG3 shows promise for targeting p53-Y220C mutation in gastric cancer

AG3, a compound with zinc chelation and Michael acceptor properties, effectively reactivates p53-Y220C in gastric cancer cells.

ClinicalJuly 6, 2026

Study on Laparoscopic Techniques for Gastric Cancer Quality of Life

A clinical trial is underway to compare the short-term quality of life outcomes between two surgical techniques for gastric cancer.

ClinicalJuly 3, 2026

Phase II Trial of HIPEC with Cisplatin and Paclitaxel for High-Risk Gastric Cancer

A phase II trial is evaluating the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin and paclitaxel for patients with gastric or gastroesophageal junction adenocarcinoma at high risk of peritoneal recurrence.

ClinicalJune 30, 2026

Phase Ib Trial of Aldesleukin with Nivolumab for Gastric Cancer with Peritoneal Metastasis

A phase Ib trial is investigating the combination of aldesleukin, nivolumab, and standard chemotherapy for gastric cancer with peritoneal metastasis.

ClinicalJune 21, 2026

FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression

FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Gastric Cancer →
Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.